Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry
A. Neil, M.D., Chief Executive Officer and Chairman of the Board,
will attend and present at the ATS 2023 Respiratory Innovation
Summit (RIS), hosted by the American Thoracic Society, on May
19-20, 2023 in Washington, DC.
Dr. Neil will present on AVTX-002 in
non-eosinophilic asthma during Showcase One: Asthma, COPD, and
Airway Inflammation Innovators at 8:30am ET on Saturday, May 20,
2023.
About ATS 2023 Respiratory Innovation
Summit
Hosted by the American Thoracic Society, the
2023 Respiratory Innovation Summit unites innovators, investors,
clinicians and advocacy groups who are leading the charge to create
powerful new treatments for deadly and crippling diseases of the
lungs and airways. This meeting historically attracts 275+ global
leaders representing all facets of the respiratory industry,
including representatives from start-ups, business development,
venture capital, government, academia and clinical medicine.
About AVTX-002
AVTX-002, Avalo’s lead development asset, is a
fully human monoclonal antibody (mAb), directed against human LIGHT
(Lymphotoxin-like, exhibits
Inducible expression, and competes with Herpes
Virus Glycoprotein D for
Herpesvirus Entry Mediator (HVEM), a receptor
expressed by T lymphocytes). There is increasing
evidence that the dysregulation of the LIGHT-signaling network
which includes LIGHT, its receptors HVEM and LTβR and the
downstream checkpoint BTLA, is a disease-driving mechanism in
autoimmune and inflammatory reactions in barrier organs. Therefore,
we believe reducing LIGHT levels can moderate immune dysregulation
in many acute and chronic inflammatory disorders, including NEA.
AVTX-002 previously demonstrated proof of concept in COVID-19
induced acute respiratory distress syndrome including reduction in
mortality and respiratory failure.
About AVTX-002 PEAK Trial
The Phase 2 PEAK Trial is a randomized,
double-blind, placebo-controlled, parallel group trial designed to
evaluate the safety and efficacy of AVTX-002 for the treatment of
poorly controlled NEA (NCT05288504). Following 12 weeks
of treatment, the efficacy and safety of AVTX-002 will be evaluated
compared with placebo. The primary endpoint is the proportion of
patients who experience any of the following asthma-related events:
(i) ≥6 additional reliever puffs of a short-acting beta-agonist
(compared to baseline) in a 24-hour period on 2 consecutive days,
or (ii) increase in inhaled corticosteroid dose ≥4 times than the
dose at baseline, or (iii) a decrease in peak flow of 30% or more
(compared to baseline) on 2 consecutive days of treatment, or (iv)
an asthma exacerbation requiring the use of systemic
corticosteroids (tablets, suspension, or injection) for at least 3
days, or (v) a hospitalization or emergency room visit because of
an asthma exacerbation.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage
biotechnology company focused on the treatment of immune
dysregulation by developing therapies that target the LIGHT
network.
LIGHT (Lymphotoxin-like,
exhibits Inducible expression, and competes
with HSV Glycoprotein D
for Herpesvirus Entry Mediator (HVEM), a
receptor expressed by T lymphocytes;
also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT
and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β
receptor (TNFRSF3), form an immune regulatory network with two
co-receptors of herpesvirus entry mediator, checkpoint inhibitor B
and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling
network). Accumulating evidence points to the dysregulation of the
LIGHT network as a disease-driving mechanism in autoimmune and
inflammatory reactions in barrier organs. Therefore, we believe
reducing LIGHT levels can moderate immune dysregulation in many
acute and chronic inflammatory disorders.
For more information about Avalo, please
visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking
statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Avalo’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Avalo’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as “projects,” “may,” “might,” “will,”
“could,” “would,” “should,” “continue,” “seeks,” “aims,”
“predicts,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” or similar expressions (including
their use in the negative), or by discussions of future matters
such as: the future financial and operational outlook; the
development of product candidates or products; timing and success
of trial results and regulatory review; potential attributes and
benefits of product candidates; and other statements that are not
historical. These statements are based upon the current beliefs and
expectations of Avalo’s management but are subject to significant
risks and uncertainties, including: Avalo's debt and cash position
and the need for it to raise additional capital in the near future;
drug development costs, timing and other risks, including reliance
on investigators and enrollment of patients in clinical trials,
which might be slowed by COVID-19 or other widespread health
events; reliance on key personnel; regulatory risks; general
economic and market risks and uncertainties, including those caused
by COVID-19 or other widespread health events; and those other
risks detailed in Avalo’s filings with the SEC. Actual results may
differ from those set forth in the forward-looking statements.
Except as required by applicable law, Avalo expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Avalo’s expectations with respect thereto or
any change in events, conditions or circumstances on which any
statement is based.
For media and investor
inquiries
Christopher Sullivan, CFO Avalo Therapeutics,
Inc.ir@avalotx.com410-803-6793
or
Chris BrinzeyICR
WestwickeChris.brinzey@westwicke.com339-970-2843
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Apr 2024 to May 2024
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From May 2023 to May 2024